Skip to main content
. 2020 Jul 23;11:1796. doi: 10.3389/fmicb.2020.01796

Figure 6.

Figure 6

(A) Shows the receptor binding domain (RBD) of SARS-CoV-2 Spike protein with human ACE-2 receptor for viral entry into host cells. (B) The interrupting mode of rilapladib (−9.7 Kcal/mol) on the interface of RBD of the Spike protein-ACE2 complex. (C) Super-position view of the binding interations of rilapladib on the interface of RBD of the Spike protein-ACE2 complex. (D) Shows the interacted aminoacid residues of rilapladib on the interface of RBD of the Spike protein-ACE2 complex.